Jupiter Orphan Therapeutics
NASDAQ: JUNSJupiter, US · Founded 2016 · Delaware corporation · 1 known investors
Find your way into Jupiter Orphan Therapeutics
Jupiter Neurosciences develops JOTROL, an enhanced resveratrol formulation designed to address neuroinflammatory and central nervous system disorders, with a Phase IIa trial underway in Parkinson's Disease, while also selling wellness supplements under the Nugevia brand through direct-to-consumer channels.
Founders & leadership
JU
Jacob UittenbogaardinChief Financial Officer
MH
Marshall HaywardChief Scientific Officer
CR
Christer RoséninChief Executive Officer and President
SE
Saleem ElmasriChief Financial Officer
AR
Alexander RoséninChief Administrative Officer
AD
Alison D. SilvaPresident and Chief Operating Officer, and Director
CW
Claes WahlestedtConsulting Chief Medical Officer
Board
NH
Nicholas HemmerlyBoard director
HW
Holger WeissBoard director
AC
Andrew CutlerBoard director
TP
Tomas PhilipsonBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 4 rounds · 2016–2026
▶$774.8KraisedSep 2026 · 1 investors · Other Health CareRule 506(b)
▶$774.8KraisedSep 2026 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Christer RosenExecutive Officer, Director
- Alison SilvaExecutive Officer, Director
- Saleem ElmasriExecutive Officer
- Marshall HaywardExecutive Officer, Director
- Alexander RosenExecutive Officer
- Nicholas HemmerlyDirector
- Holger WeissDirector
- Andrew CutlerDirector
- Tomas PhilipsonDirector
- Offering amount
- $774.8K
- Amount sold
- $774.8K
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedDec 2017 · 1 investors · Other Health CareRule 506(b)
▶$100KraisedDec 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Marshall HaywardExecutive Officer, Director
- Christer RosenExecutive Officer, Director
- Natalie McNameeDirector
- Claes WahlestedtExecutive Officer, Director
- Jacob UittenbogaardExecutive Officer, Director
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$1MraisedDec 2016 · 1 investors · Other Health CareRule 506(b)
▶$1MraisedDec 2016 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Natalie McNameeDirector
- Claes WahlestedtExecutive Officer, Director
- Jacob UittenbogaardExecutive Officer, Director
- Christer RosenExecutive Officer, Director
- Marshall HaywardExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$250KraisedJul 2016 · 1 investors · Other Health CareRule 506(b)
▶$250KraisedJul 2016 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jacob UittenbogaardExecutive Officer, Director
- Marshall HaywardExecutive Officer, Director
- Claes WahlestedtExecutive Officer, Director
- Christer RosenExecutive Officer, Director
- Offering amount
- $4.5M
- Amount sold
- $250K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Jupiter Orphan Therapeutics do?
- Jupiter Neurosciences develops JOTROL, an enhanced resveratrol formulation designed to address neuroinflammatory and central nervous system disorders, with a Phase IIa trial underway in Parkinson's Disease, while also selling wellness supplements under the Nugevia brand through direct-to-consumer channels.
- Who are Jupiter Orphan Therapeutics's investors?
- Jupiter Orphan Therapeutics's investors include Tarnagulla Ventures.
- How much funding has Jupiter Orphan Therapeutics raised?
- Jupiter Orphan Therapeutics has disclosed $2.1M raised across 4 rounds.
- Where is Jupiter Orphan Therapeutics headquartered?
- Jupiter Orphan Therapeutics is headquartered in Jupiter, US.